More News! Sanofi halts Zika Vaccine Development, citing Infection Decline and Funding Issues

Try as we might, we can’t cover all the biotech news out there! Here’s a roundup of news that didn’t make the cut this week.

  • Italian outfit Axxam has found a partner in Sanofi for its efforts in neurodegeneration
  • Scottish immuno-oncology biotech TC Biopharm has partnered with UCL, whose academics will help push its modified T cells forward
  • OSE has teamed up with the Oncology Physician Network GERCOR to conduct a combination Phase II trial in pancreatic cancer with its lead asset, Tedopi
  • Summit’s new antibiotic ridinilazole just cleared an exploratory Phase II trial designed to evaluate safety.
  • Sanofi halted the development of its Zika vaccines, citing a falling infection rate and limited funding from the US government
  • InflaRx’s treatment for acne inversa, IFX-1, has cleared an exploratory Phase IIa trial

Images via FACTORYPIC, Damsea, kungverylucky / shutterstock.com

SaveSave

SaveSave

Let's Continue The Conversation

Feel free to send us comments about this article to comments@labiotech.eu and/or comment on that article on social media.

We use cookies to give you the best experience and for advertising purposes. By accepting, you support our independent media and it's freely accessible content.